



## **CORINDUS LAUNCHES CORPATH ROBOTIC-ASSISTED CORONARY INTERVENTION PROGRAM TO INCREASE PHYSICIAN SAFETY AT MASSACHUSETTS GENERAL HOSPITAL**

*Collaboration brings benefits of robotics to leading cardiac cath lab*

**WALTHAM, MA.—JANUARY 5, 2016**—Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS] today announced the launch of a CorPath<sup>®</sup> robotic-assisted coronary intervention program at [Massachusetts General Hospital \("MGH"\)](#) and the installation of its first CorPath System. Involvement in the robotic-assisted coronary intervention program will allow physicians at MGH to perform percutaneous coronary interventions (PCI) using the [CorPath System](#) while protected from radiation exposure in the system's radiation-shielded control cockpit.

The CorPath System is the first and only FDA-cleared medical device to bring robotic-assisted precision to PCI procedures while protecting medical professionals from radiation exposure occurring in hospital catheterization laboratories. The CorPath robotic-assisted coronary intervention program at MGH brings the safety and benefits of the CorPath System to cath lab patients and workers today, as well as creating opportunities for furthering the technology in the future.

"Emerging technologies should contribute to the well-being of patients and physicians," said Doug Drachman, MD, Director of MGH's Cardiovascular Fellowship Program. "Robotic assistance provides enhanced visualization and potentially increased accuracy. Coupled with radiation reduction for clinicians, these advances may not only improve care, but also the long term health of patient and provider."

Today, interventional procedures performed in hospital cath labs are a leading source of radiation exposure for medical personnel which has been linked to the development of cataracts, cancer, and brain and thyroid diseases. The CorPath System allows interventional cardiologists to perform procedures in a protected cockpit just a few feet away from the patient bed side. Seated in the radiation-protected cockpit, the physician uses intuitive digital controls to robotically advance guidewires, angioplasty balloons and stents through coronary arteries.

"Leading institutions such as MGH routinely perform long, complex procedures, which may have the most opportunity to benefit from the precision, reduced radiation exposure, and ergonomics afforded by vascular robotics," said David Handler, President and Chief Executive Officer of Corindus. "Collaboration between Corindus and a leading clinical facility such as MGH can accelerate the education, awareness and adoption of this important technology in cath labs throughout the United States and beyond."

### **About Corindus Vascular Robotics, Inc.**

[Corindus Vascular Robotics, Inc.](#) is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company's CorPath System is the first FDA-cleared medical device to bring robotic-assisted precision to PCI procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded cockpit to advance stents and guidewires with millimeter-by-millimeter precision. The cockpit allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to radial and complex PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual PCI procedures. Corindus stands

behind its product with its unique \$1,000 hospital credit "One Stent Program." For additional information, visit [www.corindus.com](http://www.corindus.com), and follow @CorindusInc.

*Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus' beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus' control. Examples of such statements include statements regarding the potential benefits of our CorPath System and robotic-assisted PCI for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. More information on potential factors that could affect Corindus' financial results is included from time to time in the "Forward Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Corindus' periodic and current filings with the SEC, as well as those discussed under the "Risk Factors" and "Forward Looking Statements" section of Corindus' Annual Report on Form 10-K filed with the SEC on March 30, 2015 and available on Corindus' website at <http://www.corindus.com/about-corindus/investor-relations>. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date.*

###

**Media Contacts:**

Corindus Vascular Robotics, Inc.

Brett Prince

(508) 653-3335 ext. 231

[Brett.prince@corindus.com](mailto:Brett.prince@corindus.com)

Yuliya Kutuzava

(203) 504-8230 ext. 131

[corindus@knbpr.com](mailto:corindus@knbpr.com)

Jamar Ismail

(415) 513-1282

[ir@corindus.com](mailto:ir@corindus.com)